Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

New study shows Probi strain supports and improves cognitive performance

In a newly published study Probi´s proprietary strain L. plantarum HEAL9 (HEAL9™) was shown to significantly improve cognitive performance. The result of the study is encouraging ahead of Probi's launch of a new product in the gut-brain area. Consumer interest in mental health and wellness is rapidly growing and the understanding of the important connection between the microbiome in the gut and mood, cognition and mental health continues to increase. Probiotic supplements supporting mental health and wellness are forecasted to have a significant market growth of 44% in the coming 10

Spinnova receives Business Finland R&D grant for developing SPINNOVA® fibre from new raw materials

SPINNOVA PLC, PRESS RELEASE 14 AUGUST 2023 AT 11 A.M. EEST   Spinnova receives Business Finland R&D grant for developing SPINNOVA® fibre from new raw materials   Spinnova has received a grant of maximum EUR 1.9 million for its research and development (R&D) work from Business Finland for the period 15 April 2023 – 14 April 2025. The grant amount represents 50% of the project’s total cost estimate totalling EUR 3.9 million. The product development project aims for pilot-scale production of SPINNOVA® fibre from textile and agricultural waste streams. The refining environment to

Dicot confirms planned start date in August for its phase 1 study

Press release: Uppsala, August 14, 2023. The potency drug developer Dicot announces that the decision from the Swedish Medical Products Agency on the clinical trial application is expected within two weeks and that the company is ready to start the study in August according to the previously communicated schedule.Dicot has completed all preparations required for the start of the planned phase 1 trial of its potency drug candidate LIB-01. The round of questions with the Medical Products Agency and the Ethical Review Authority, which is part of the application process, was completed during

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 115 - 14 AUGUST 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Compliance with MAR

Menhaden Resource Efficiency PLC (the “Company”) LEI: 2138004NTCUZTHFWXS17     Compliance with Market Abuse Regulation – Closed Period   14 August 2023   The Company confirms that:   a) all inside information which the Directors and Company may have had has been notified to a Regulated Information Service (“RIS”);   b) the Company’s net asset value per share is calculated and announced through a RIS on a daily basis; and   c) the Company has no reason to believe that there will be any material difference between the net asset value per share as

Irisity reappoints Anna Forsberg as new Interim Chief Financial Officer

Irisity AB (publ), a leading AI video analytics provider, is pleased to announce the return of Anna Forsberg as its Interim Chief Financial Officer, effective September 1, 2023. Anna Forsberg previously served with distinction in this capacity from February 2022 to November 2022.Irisity reappoints Anna Forsberg as new Interim Chief Financial Officer.     Irisity AB (publ), a leading AI video analytics provider, is pleased to announce the return of Anna Forsberg as its Interim Chief Financial Officer, effective September 1, 2023. Anna Forsberg previously served with distinction in

Kid ASA - Invitation to presentation of Second quarter 2023 results

Lier, 14 August 2023: Kid ASA will release its second quarter 2023 results on Thursday 24 August 2023. The quarterly report and presentation material will be available on http://investor.kid.no and http://newsweb.no from 07:30 CEST. The results will be presented at 09:00 CEST by CEO Anders Fjeld and CFO Mads Kigen at the offices of Arctic Securities, Haakon VIIs gate 5, 0161 Oslo. The presentation will be broadcasted as a live webcast in English and a recorded version will be made available at http://investor.kid.no. Please sign up for the webcast with the following link and you can

Desert Control Q2 2023 Report and Interim Financial Results | Webcast presentation 24 August 2023 10:00 CET

ISSUER DESERT CONTROL AS Sandnes, Norway 14 August 2023: Desert Control Q2 2023 Report and InterimFinancial Result will be released on Thursday 24 August 2023 at 07.30 AM CentralEuropean Time (Oslo)The Q2 Report and presentation will be made available athttps://www.desertcontrol.com/investorsA webcast presentation in English will be hosted on Thursday 24 August 2023 at10.00 AM Central European Time.Registration:https://go.desertcontrol.com/Q2-2023After the presentation, there will be a Q&A session. Questions can be submittedin advance to leonard.chaparian@

Repurchase of Truecaller B shares in week 32, 2023

During 7 August 2023 and 11 August 2023 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 1,025,000 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 7 June 2023. The share buyback programme will run between 7 June up until the 2024 AGM which will be held in May 2024, and is carried out in accordance “Emittentregelverket”.   On the Annual General Meeting 2023 the Board was authorized to buy back B-shares up until

Valmet to supply machine vision systems to Shanxi Qiangwei Paper in China

Valmet Oyj’s trade press release on August 14, 2023 at 9:40 a.m. EESTValmet has received an order from Shanxi Qiangwei Paper Co., Ltd. to supply machine vision systems for Qiangwei’s paper machine PM 6. The scope of supply includes a Valmet IQ Web Inspection System, a Valmet IQ Web Monitoring System and winder control with target-stop functionality. The investment aims to improve the operating efficiency and optimize the final paper quality of the PM 6. The order was included in Valmet’s orders received of the second quarter 2023. The delivery will take place in the first quarter 2024.

GARO Entity PRO – third-party certified wall box with unique security solution

GARO has elected to third-party certify GARO Entity Pro to ensure that the product is quality assured and that it adheres to current directives, laws and standards, and passes the stringent testing carried out during product development. GARO Entity Pro thus has an approved unique built-in solution for electrical safety in the wall box. End users, customers and installation engineers can therefore be confident that the product delivers what it promises.    “Throughout the GARO Entity development project, we have had an uncompromising focus on product safety. This has been our main

Veg of Lund AB - Interim report Q2 2023

Increased sales at lower costApril–June 2023 · Net sales amounted to TSEK 1,4580 (1 070). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK-7,824 (-11,291), and EBIT amounted to TSEK -7,842 (-11,343). · Net profit amounted to TSEK -8,069 (-11,183). January–June 2023 · Net sales amounted to TSEK 3,281 (1 524). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK-16,102 (-29,004), and EBIT amounted to TSEK -16,173 (-29,107). · Net profit amounted to TSEK -16,687 (-29,182). Summary of the Group’s

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

· Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment · The patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor reduction maintained · Consistently good safety and tolerability profile Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the ongoing phase 2a

Notice of extra general meeting in FlexQube AB (publ)

The shareholders of FlexQube AB (publ), reg. no. 556905-3944, (the "Company") are hereby invited to the extra general meeting to be held on Wednesday 30 August 2023, at 14:00 CET in the Company’s premises at Neongatan 8, 431 53 in Mölndal. Right to attend the general meeting Shareholders wishing to attend the extra general meeting must: i. on the record date, which is Tuesday 22 August 2023, be registered in the share register maintained by Euroclear Sweden AB; and ii. notify their participation at the general meeting no later than Thursday 24 August 2023. Notice of

Biosergen publishes interim report for first quarter 2023

Monday, August 14, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)Summary of the Interim Report for Q2 2023 2023 2022 2023 2022 2022TSEK April-June April-June Jan-June Jan-June Jan-Dec Profit/loss Other income 2.456 1.409 7.771 2.726 5.183Profit/loss before -8.038 -7.963 -13.067 -12.981 -34.

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September

XNK Therapeutics AB today announced that two posters, regarding bladder cancer and Acute Myeloid Leukemia (AML) respectively, will be presented at the 20[th] Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company’s leading natural killer (NK) cells therapies. Two abstracts have been accepted for presentation at the meeting. The data have been generated in collaboration with XNK’s external partners, Anders Ullén and Fernanda Costa Svedman at

The Board of Directors in FlexQube intends to resolve a fully guaranteed rights issue of approximately 75MSEK and explore the conditions to carry out directed share issue of approximately 25MSEK

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES PURSUANT TO APPLICABLE LAW. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Mölndal, August 14, 2023 The Board of Directors in FlexQube intends to resolve on a fully guaranteed

Elkem ASA - Initiation of a share buyback

Oslo, 14 August 2023 Elkem ASA ("Elkem" or the "Company") has decided to initiate a buyback of up to 2 million of its own shares. The shares will be used as settlement in the Company's share-based incentive scheme. The buybacks will be made in accordance with the authorisation granted to the board of directors by the Company's annual general meeting held on 28 April 2023. According to the authorisation, shares up to 10% of the share capital may be purchased at a minimum of NOK 1 and a maximum of NOK 150 per share. The authorisation is valid until the annual general meeting in 2024.

2020 Bulkers Ltd. (2020) – Invitation to webcast and conference call Q2 2023 results

2020 Bulkers Ltd. will release its financial results for the second quarter of 2023 on Wednesday, August 16, 2023. A conference call and webcast will be held at 3:00 PM CET. The earnings report and presentation will be available from the Investor Relations section on www.2020bulkers.com on the same day. In order to listen to the presentation, you may do one of the following: Listen-only webcast (including the slide presentation): https://channel.royalcast.com/landingpage/hegnarmedia/20230816_2/ or you can click the “Webcast” link on www.2020bulkers.com/investor-relations/

AcuCort joins Röda webben ahead of commercialization

AcuCort has joined the Röda webben services which is coordinated by the industry organization for pharmaceutical companies conducting research - LIF. The affiliation is a step towards the upcoming commercialization of the company's pharmaceutical product Zeqmelit®.Within the pharmaceutical industry, there are elaborate complaint and recall procedures. The guidelines are collected on the so-called Röda webben and describe how complaints and withdrawals of medicines should be handled in Sweden. These guidelines constitute standards for the pharmaceutical industry with products on the Swedish

NAGRA selects Reltime to enable a Super App Wallet and Digital services for Telecom operators globally

Oslo, Norway – 14 August 2023 - Reltime, an award-winning provider of next-generation Web3 platform and services has today announced an agreement with NAGRA, the digital TV division of the Kudelski Group, to enable Super Apps through a non-custodian wallet and digital services for Telecom operators globally. NAGRA is the world’s leading independent provider of content protection and multiscreen solutions for the media and entertainment industry with over 550 customers (serving over 400m subscribers) globally. The NAGRA and Reltime partnership represents a ground-breaking

Repurchases of shares by EQT AB during week 32, 2023

Between 7 August 2023 and 11 August 2023 EQT AB (LEI code 213800U7P9GOIRKCTB34) (“EQT”) has repurchased in total 393,926 own ordinary shares (ISIN: SE0012853455) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 1,800,000 own ordinary shares for a total maximum amount of SEK 500,000,000 that EQT announced on 14 July 2023. The repurchase program, which runs between 17 July 2023 and 25 August 2023, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

There are no items matching the current filter
There are no more items matching the current filter
Back to top